|
|
Vaccine Detail
|
MUC1-Overexpressing CD133+ Colorectal Cancer Stem Cell Lysate Vaccine |
| Vaccine Information |
- Vaccine Name: MUC1-Overexpressing CD133+ Colorectal Cancer Stem Cell Lysate Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Whole-cell lysate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Guo et al., 2020)
- Immunization Route: subcutaneous injection
- Description: A whole-cell lysate vaccine prepared from CD133⁺ colorectal cancer stem cells (CCSCs) isolated from the SW620 human colorectal adenocarcinoma cell line by magnetic-activated cell sorting (MACS). CCSCs overexpressed MUC1, identified as a candidate tumor-associated antigen through bioinformatics analysis of 333 colorectal cancer samples. Lysates were prepared by repeated freeze-thaw cycles. BALB/c nude mice were immunized subcutaneously three times at 10-day intervals with 2×10^5 cell lysates, followed by challenge with 2×10^6 SW620 cells. Vaccination reduced tumor growth, decreased CD133⁺ cells (4.39% vs. 21.7% in the shMUC1 CCSC group) and ALDH⁺ cells (1.79% vs. 14.00% in the shMUC1 CCSC group) in tumors, and increased NK cytotoxicity, ADCC, CDC, perforin, granzyme B, and IFN-γ. CD19⁺ B cells reached 30.5% (vs. 13.9% in PBS controls) and memory B cells 4.62% (vs. 1.40% in PBS controls), with elevated anti-MUC1 antibody levels. MUC1 knockdown (shMUC1) partially impaired vaccine immunogenicity and antitumor efficacy, supporting an important role for MUC1 in CCSC vaccine activity (Guo et al., 2020).
|
| Host Response |
|
|
| References |
Guo et al., 2020: Guo M, Luo B, Pan M, Li M, Zhao F, Dou J. MUC1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine. International immunopharmacology. 2020; 85; 106631. [PubMed: 32470879].
|
|
